Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Anaïs Schavgoulidze, Aurore Perrot
NEW THERAPIES IN MULTIPLE MYELOMA Multiple myeloma is the second most common hemopathy in Western countries. The development of the therapeutic arsenal has significantly improved patients' prognosis. In the early 2000s, autograft, the addition of immunomodulatory drugs and proteasome inhibitors have undoubtedly changed the face of the disease. In the last decade, a new chapter has opened, targeted therapies led by anti-CD38 and more recently the introduction of CAR T-cells and bispecific antibodies. Because of the survival improvement, quality of life is now a major concern as well as personalized treatment (adapted to cytogenetic risk or treatment response [minimal residual disease]) to overcome prognosis heterogeneity...
May 2022: La Revue du Praticien
#22
Najat Lasri, Fatimazahra Lahlimi, Mohammed Ilias Tazi, Sophie Rigaudeau
IgD myeloma is an extremely rare haemopathy with severe clinical presentation. It can be confused with non-secretory or free light chain myeloma. We here report the case of a 72-year old female patient presenting with bone pain and diffuse ecchymosis and deterioration of her general condition. Laboratory tests showed monoclonal gammopathy associated with severe acute renal failure and low total protein (TP) (48%) with factor X deficiency. Etiological assessment confirmed the diagnosis of IgD lambda myeloma stage IIIb, according to Durie and Salmon, International Staging System (ISS) score III unfavorable cytogenetics...
2022: Pan African Medical Journal
#23
JOURNAL ARTICLE
Emilie Chalayer, Alexis Talbot, Laurent Frenzel, Lionel Karlin, Philippe Collet, Denis Guyotat, Michel Attal, Xavier Leleu, Bernard Tardy
BACKGROUND: Venous thromboembolism (VTE) is a concern for patients with newly diagnosed multiple myeloma. OBJECTIVES: We aimed to evaluate VTE incidence, risk factors, and risk score. PATIENTS/METHODS: We performed a substudy of the "Intergroupe Francophone du Myelome 2009" randomized controlled trial. RESULTS: We assessed 700 patients receiving lenalidomide/bortezomib/dexamethasone, followed or not by autologous hematopoietic stem cell transplantation...
May 12, 2022: Journal of Thrombosis and Haemostasis: JTH
#24
JOURNAL ARTICLE
Tristan Bintner, Valérie Coulon, Quentin Cabrera, Thierry Klein
An 88-year-old man is sent to hospital because of a rapid worthening of his general state. A myelogram is obtained following the discovery of hypercalcemia associated with a diminished glomerular filtration rate and the discovery of osteolytic lesions, showing a massive proliferation of plasma cells. The lack of plasma and urine detection of both monoclonal antibodies and immunoglobulin light chains, as well as an immature plasma cell phenotype, suggest the diagnosis of non-secretory multiple myeloma. This article aims to describe the atypical clinical presentation of a rare case of multiple myeloma...
February 1, 2022: Annales de Biologie Clinique
#25
REVIEW
Hartmut Goldschmidt
CLINICAL ISSUE: Multiple myeloma (MM) is a malignancy of hematopoetic system and is associated with destruction of bone, suppressed bone marrow function and renal failure. It is characterized by strong proliferation of malignant plasma cells. STANDARD TREATMENT: Classic therapies contained an alkylating agent and a glucocorticoid. In the 1990s, treatments were supplemented with transplantation of peripheral blood stem cells. TREATMENT INNOVATIONS: During the 2000s, new therapies emerged, combining an immunomodulator (thalidomide, lenalidomide or pomalidomide), a proteasome inhibitor (bortezomib, carfilzomib or ixazomib), and a monoclonal antibody against CD38...
January 2022: Der Radiologe
#26
REVIEW
Christos Sachpekidis, Hartmut Goldschmidt, Antonia Dimitrakopoulou-Strauss
BACKGROUND: Imaging plays a pivotal role in the management of multiple myeloma (MM). Besides morphological imaging methods, such as whole-body X‑ray, computed tomography (CT) and magnetic resonance imaging (MRI), the hybrid modality positron emission tomography/CT (PET/CT) using the glucose analogue 18 F‑fluorodeoxyglucose (18 F‑FDG) as radiotracer is increasingly used. OBJECTIVES: Aim of this review article is to outline the major applications of PET/CT in the diagnosis and management of MM, and to provide hints on the reading and interpretation...
January 2022: Der Radiologe
#27
REVIEW
Benoît Ferment, Bertrand Arnulf
Despite recent therapeutic advances, multiple myeloma remains an incurable disease and the therapeutic options currently available are insufficient in refractory patients. Chimeric antigen receptor (CAR)-expressing T cells are an innovative form of adoptive cell therapy in which T cells are reprogrammed to induce an anti-tumor response. Following the successful use of CAR-T cells in the treatment of other B-cell malignancies, CAR-T-based strategies which target the B cell maturation antigen (BCMA) on the surface of tumor plasma cell are now being used in MM patients...
October 2021: Bulletin du Cancer
#28
REVIEW
Guillaume Escure, Salomon Manier
Immunotherapies have recently emerged as potential game changers in the treatment of multiple myeloma (MM). Those include monoclonal antibodies (targeting CD38 or CS1), bispecific antibodies (BsAb, mainly targeting BCMA, GPRC5D or FcRH5), antibody-drug conjugate (mainly targeting BCMA) and CAR-T cells (mainly targeting BCMA). BsAb have the capacity to bind two different antigens, one at the tumor cell surface and one on T cells (CD3), recreating the immune synapse. In this article, we discuss the main clinical data on BsAb in MM, as well as their different constructs and the potential mechanism of resistance...
October 2021: Bulletin du Cancer
#29
REVIEW
Sabrina Barrière, Nathan El-Ghazzi, Manon Garcia, Romain Guièze
Bispecific antibodies are novel approaches of immunotherapy engaging immune cells to destroy tumor cells. Their structure is variable and underlies their pharmacocinetic properties. These coumpounds are now being evaluated across multiple hematological malignancies. The anti-CD3/CD19 antibody blinatumomab is the first in class and have been approved for the treatment of patients with Ph-negative B-cell acute lymphoblastic leukemia. Other emerging applications are lymphoma, multiple myeloma and acute myeloid leukemia...
October 2021: Bulletin du Cancer
#30
JOURNAL ARTICLE
Christian Chabannon, Jessica Lemaitre, Régis Peffault de Latour, Bénédicte Neven, Jacques-Olivier Bay, Marie Robin, Jurgen Kuball, Sofie Terwel, Mohamad Mohty, Ibrahim Yakoub-Agha
CAR-T Cells are gene therapy medicinal products, a subcategory of Advanced Therapy Medicinal Products as defined in the EC Regulation 1394/2007. They may represent the first example of such medicinal products that are industry-manufactured and commercialized on a large scale. Their very nature, their manufacturing processes, pricing and conditions upon which they were approved by regulatory agencies, all lead the latter to require long-term follow-up after marketing approval with a view for a better definition of CAR-T Cells safety profile and efficacy profile in real world conditions...
October 2021: Bulletin du Cancer
#31
REVIEW
Marc-André Weber, Andrea Baur-Melnyk
CLINICAL ISSUE: Multiple myeloma is a clonal B‑lymphocyte neoplasm of terminally differentiated plasma cells and accounts for approximately 10% of all hematologic malignancies. Reduction of bone mass, seen on computed tomography (CT) as focal osteolysis, or general osteopenia is mainly caused by tumor-induced resorption of bone. STANDARD RADIOLOGICAL METHODS: Imaging methods are used in multiple myeloma to record the extent of various dimensions of the disease manifestations (damage to bone substance, bone marrow infiltration, extramedullary involvement) and the disease course...
January 2022: Der Radiologe
#32
REVIEW
Laila König, Klaus Herfarth
BACKGROUND: Treatment options for patients with solitary plasmacytoma (SP) or multiple myeloma (MM) should be discussed in an interdisciplinary context. This systematic review focuses on the importance of radiotherapy in MM and SP. OBJECTIVE: Summary of local radio-oncological treatment options for patients with SP and MM. MATERIALS AND METHODS: Based on a systematic literature search, the current evidence on the topic was analyzed and summarized...
January 2022: Der Radiologe
#33
COMMENT
Ann S Lee, Roger Y Tsang, Irwindeep Sandhu
No abstract text is available yet for this article.
October 25, 2021: Canadian Medical Association Journal: CMAJ
#34
REVIEW
Antonio Vogelsberg, Christian M Schürch, Falko Fend
BACKGROUND: Multiple myeloma (MM) is one of the most common hematological neoplasms and accounts for approximately 1% of human cancers. OBJECTIVES: Description of current diagnostics and classification of MM and related plasma cell neoplasms from the pathology viewpoint. MATERIALS AND METHODS: Current knowledge regarding pathology and genetics of MM is summarized and tissue-based diagnostics following international consensus classifications and the current S3 guideline are described...
October 18, 2021: Der Radiologe
#35
LETTER
Arthur Bobin, Maéva Kyheng, Stéphanie Guidez, Cécile Gruchet-Merouze, Valentine Richez, Alain Duhamel, Lionel Karlin, Brigitte Kolb, Mourad Tiab, Carla Araujo, Nathalie Meuleman, Jean-Valère Malfuson, Pascal Bourquard, Pascal Lenain, Aurore Perrot, Murielle Roussel, Arnaud Jaccard, Marie-Odile Petillon, Karim Belhadj-Merzoug, Marie-Lorraine Chretien, Jean Fontan, Philippe Rodon, Anna Schmitt, Fritz Offner, Laurent Voillat, Sophie Cereja, Frédérique Kuhnowski, Sophie Rigaudeau, Olivier Decaux, Catherine Humbrecht-Kraut, Jamile Frayfer, Olivier Fitoussi, Damien Roos-Weil, Jean Claude Eisenmann, Véronique Dorvaux, Eric G Voog, Philippe Moreau, Hervé Avet-Loiseau, Cyrille Hulin, Thierry Facon, Xavier Leleu
No abstract text is available yet for this article.
March 2022: Leukemia
#36
RANDOMIZED CONTROLLED TRIAL
Philippe Moreau, Cyrille Hulin, Aurore Perrot, Bertrand Arnulf, Karim Belhadj, Lotfi Benboubker, Marie C Béné, Sonja Zweegman, Hélène Caillon, Denis Caillot, Jill Corre, Michel Delforge, Thomas Dejoie, Chantal Doyen, Thierry Facon, Cécile Sonntag, Jean Fontan, Mohamad Mohty, Kon-Siong Jie, Lionel Karlin, Frédérique Kuhnowski, Jérôme Lambert, Xavier Leleu, Margaret Macro, Frédérique Orsini-Piocelle, Murielle Roussel, Anne-Marie Stoppa, Niels W C J van de Donk, Soraya Wuillème, Annemiek Broijl, Cyrille Touzeau, Mourad Tiab, Jean-Pierre Marolleau, Nathalie Meuleman, Marie-Christiane Vekemans, Matthijs Westerman, Saskia K Klein, Mark-David Levin, Fritz Offner, Martine Escoffre-Barbe, Jean-Richard Eveillard, Réda Garidi, Tahamtan Ahmadi, Maria Krevvata, Ke Zhang, Carla de Boer, Sanjay Vara, Tobias Kampfenkel, Veronique Vanquickelberghe, Jessica Vermeulen, Hervé Avet-Loiseau, Pieter Sonneveld
BACKGROUND: CASSIOPEIA part 1 showed superior depth of response and significantly improved progression-free survival with daratumumab, bortezomib, thalidomide, and dexamethasone (D-VTd) versus bortezomib, thalidomide, and dexamethasone (VTd) as induction and consolidation in patients with autologous stem-cell transplant (ASCT)-eligible newly diagnosed multiple myeloma. In part 2, we compared daratumumab maintenance versus observation only. METHODS: CASSIOPEIA is a two-part, open-label, randomised, phase 3 trial of patients aged 18-65 years with newly diagnosed multiple myeloma and Eastern Cooperative Oncology Group performance status 0-2, done in 111 European academic and community practice centres...
October 2021: Lancet Oncology
#37
Salma Fares, Halima Hadri, Mohamed Rachid, Tarik Moutiqui, Bouchra Oukkache, Asmaa Quessar
High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (AHSCT) is the gold standard treatment for multiple myeloma in subjects aged ≤ 65 years. In developing countries, AHSCT without cryopreservation reduces the costs of hospitalization and all necessary equipments. We conducted a longitudinal, prospective, open study to evaluate this procedure at the Department of Clinical Hematology, Casablanca, Morocco. Data from the medical records of 64 patients were collected over a period of 24 months...
2021: Pan African Medical Journal
#38
JOURNAL ARTICLE
K Peignaux-Casasnovas, G Truc, C Rossi, O Casasnovas
The management of myeloid and lymphoid disease is essentially based on chemotherapy and targeted therapies. Since radiotherapy could be responsible for severe late toxicities, essentially due to conventional bidimensional irradiation techniques, many trials have attempted to omit radiotherapy or to scale down the dose in their therapeutic strategy. Nevertheless, radiotherapy still plays a role for curative or symptomatic purposes.
August 28, 2021: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique
#39
JOURNAL ARTICLE
Michèle Reboud-Ravaux
The proteasome is the central component of the adaptable ubiquitin proteasome system (UPS) discovered in the 1980's. It sustains protein homeostasis (proteostasis) under a large variety of physiological and pathological conditions. Its dysregulation has been often associated to various human diseases. Its potential regulation by modulators has emerged as promising avenue to develop treatments of various pathologies. The FDA approval in 2003 of the proteasome inhibitor bortezomib to treat multiple myeloma, then mantle lymphoma in 2006, has considerably increased the clinical interest of proteasome inhibition...
2021: Biologie Aujourd'hui
#40
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
May 2021: Zeitschrift Für Gastroenterologie
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
